Bilal Chaudhry

Bilal Chaudhry
Bilal Chaudhry is an associate in Weil’s Mergers & Acquisitions practice and is based in New York. Mr. Chaudhry participates in the representation of public and private companies in mergers, acquisitions and divestitures.

Mr. Chaudhry has participated in advising:

  • Dow Inc. in its approximately $40 billion spin-off from DowDuPont Inc. as part of DowDuPont's separation into three independent, publicly traded companies.
  • Eli Lilly and Company in its approximately $8 billion acquisition of Loxo Oncology, Inc.
  • syncreon Holdings Group B.V., and its affiliates, in its groundbreaking, cross-border balance sheet restructuring involving approximately $1.1 billion of funded debt, effected through an English scheme of arrangement pursuant to the Companies Act 2006 and ancillary processes in the United States and Canada.

Mr. Chaudhry received his J.D., cum laude and with honors, from Fordham University School of Law where he was a Paul Fuller Scholar. Mr. Chaudhry received his B.S., cum laude, from the Leonard N. Stern School of Business at New York University.